Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer

This randomized phase II study investigated pemetrexed in combination with the epidermal growth factor receptor (EGFR)-targeting monoclonal antibody matuzumab compared with pemetrexed alone as second-line therapy for patients with advanced non-small cell lung cancer.

Bibliographic Details

Main Authors:	Schiller, Joan H. (Author) , von Pawel, Joachim (Author) , Schütt, Philipp (Author) , Ansari, Rafat H. (Author) , Thomas, Michael (Author) , Saleh, Mansoor (Author) , McCroskey, Robert D. (Author) , Pfeifer, Wolfgang (Author) , Marsland, Thomas A. (Author) , Kloecker, Goetz H. (Author) , Sebastian, Martin (Author) , Pirker, Robert (Author) , Kurek, Raffael (Author) , Beadman, Claire (Author) , Socinski, Mark A. (Author)
Format:	Article (Journal)
Language:	English
Published:	2010
In:	Journal of thoracic oncology Year: 2010, Volume: 5, Issue: 12, Pages: 1977-1985
ISSN:	1556-1380
DOI:	10.1097/JTO.0b013e3181f4a5c9
Online Access:	Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1097/JTO.0b013e3181f4a5c9 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1556086415318712
Author Notes:	Joan H. Schiller, Joachim von Pawel, Philipp Schütt, Rafat H. Ansari, Michael Thomas, Mansoor Saleh, Robert D. McCroskey, Wolfgang Pfeifer, Thomas A. Marsland, Goetz H. Kloecker, Martin Sebastian, Robert Pirker, Raffael Kurek, Claire Beadman, and Mark A. Socinski